JPS632414B2 - - Google Patents
Info
- Publication number
- JPS632414B2 JPS632414B2 JP6232581A JP6232581A JPS632414B2 JP S632414 B2 JPS632414 B2 JP S632414B2 JP 6232581 A JP6232581 A JP 6232581A JP 6232581 A JP6232581 A JP 6232581A JP S632414 B2 JPS632414 B2 JP S632414B2
- Authority
- JP
- Japan
- Prior art keywords
- choline
- cdp
- body weight
- present
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 229960001284 citicoline Drugs 0.000 claims description 3
- 230000037396 body weight Effects 0.000 description 23
- 239000000203 mixture Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 9
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 8
- 229960001231 choline Drugs 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012857 radioactive material Substances 0.000 description 3
- 239000000941 radioactive substance Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XGCDBGRZEKYHNV-UHFFFAOYSA-N 1,1-bis(diphenylphosphino)methane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CP(C=1C=CC=CC=1)C1=CC=CC=C1 XGCDBGRZEKYHNV-UHFFFAOYSA-N 0.000 description 1
- SBAMCHUPHQPWLM-UHFFFAOYSA-N 4-[2-(2,5-dioxopyrrol-1-yl)ethyl]benzenediazonium Chemical compound O=C1C=CC(=O)N1CCC1=CC=C([N+]#N)C=C1 SBAMCHUPHQPWLM-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000826860 Trapezium Species 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6232581A JPS57179115A (en) | 1981-04-23 | 1981-04-23 | Medicinal composition containing cytidine phosphocholine or salt for oral administration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6232581A JPS57179115A (en) | 1981-04-23 | 1981-04-23 | Medicinal composition containing cytidine phosphocholine or salt for oral administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57179115A JPS57179115A (en) | 1982-11-04 |
| JPS632414B2 true JPS632414B2 (enrdf_load_stackoverflow) | 1988-01-19 |
Family
ID=13196864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6232581A Granted JPS57179115A (en) | 1981-04-23 | 1981-04-23 | Medicinal composition containing cytidine phosphocholine or salt for oral administration |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57179115A (enrdf_load_stackoverflow) |
-
1981
- 1981-04-23 JP JP6232581A patent/JPS57179115A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57179115A (en) | 1982-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2571693B2 (ja) | フェノフィブレ−ト含有顆粒状医薬品及びその製法 | |
| JP3667778B2 (ja) | スフェロイド製剤 | |
| US4462991A (en) | Method of increasing oral absorption of polar bioactive agents | |
| US4708868A (en) | Oral anti-diabetic pharmaceutical forms and the preparation thereof | |
| US5811126A (en) | Controlled release matrix for pharmaceuticals | |
| EP0357793B1 (en) | Suspended-release preparation prepared by using alginates | |
| PT642785E (pt) | Sistemas de hidrogel heterodisperso de libertacao sustida | |
| US4696815A (en) | Anti-diabetic pharmaceutical forms and the preparation thereof | |
| JPH0367045B2 (enrdf_load_stackoverflow) | ||
| EP0138216A2 (en) | Sustained-release IFN preparation for parenteral administration | |
| US4386077A (en) | Pharmaceutical composition for oral administration containing cytidine diphosphocholine | |
| JP3744941B2 (ja) | プロスタグランジンｉ誘導体徐放性製剤 | |
| SK278868B6 (sk) | Prípravok s retardovaným uvoľňovaním účinnej látky | |
| KR890000907B1 (ko) | 안정한 현탁액 제조용 고체 약물 제형의 제조방법 | |
| RU2240784C1 (ru) | Лекарственное средство на основе арбидола | |
| RU2272623C2 (ru) | РАСТВОР ТЕТРАГИДРАТА МОНОНАТРИЕВОЙ СОЛИ N-[O-(п-ПИВАЛОИЛОКСИБЕНЗОЛСУЛЬФОНИЛАМИНО)БЕНЗОИЛ]ГЛИЦИНА И ГОТОВАЯ ЛЕКАРСТВЕННАЯ ФОРМА НА ЕГО ОСНОВЕ | |
| JPS5940137B2 (ja) | 経口投与用医薬組成物 | |
| DE68917727T2 (de) | Verfahren zum regeln der absorptionsrate von arzneimitteln sowie arzneimittelformulierung. | |
| GB2047096A (en) | Naftidrofuryl composition for immediate and delayed release | |
| US4416898A (en) | Therapeutic uses of methionine | |
| JPS632414B2 (enrdf_load_stackoverflow) | ||
| HU206261B (en) | Process for producing pharmaceutical compositions suitable for treating pulmonary hypertension caused by neutralization by heparin protemin, and comprising 7-oxabicyclo/2.2.1/-5-heptanoic acid derivative as active ingredient | |
| US20040092480A1 (en) | Medicinal composition | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| BR112020000207A2 (pt) | composição farmacêutica de forma de dosagem oral de enzalutamida e processo para preparar a composição farmacêutica de forma de dosagem oral de enzalutamida |